Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Hysterectomy-corrected rates of endometrial cancer among women younger than age 50 in the United States.

Temkin SM, Kohn EC, Penberthy L, Cronin KA, Rubinsak L, Dickie LA, Minasian L, Noone AM.

Cancer Causes Control. 2018 May;29(4-5):427-433. doi: 10.1007/s10552-018-1018-z. Epub 2018 Mar 1.

PMID:
29497884
2.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report.

Lheureux S, McCourt C, Rimel BJ, Duska L, Fleming G, Mackay H, Mutch D, Temkin SM, Lynn J, Kohn EC.

Gynecol Oncol. 2018 Feb 22. pii: S0090-8258(18)30124-0. doi: 10.1016/j.ygyno.2018.02.005. [Epub ahead of print] Review.

PMID:
29477660
3.

Editorial: New Approaches to Radiation-Therapeutic Agent Cancer Care for Women.

Kunos CA, Kohn EC.

Front Oncol. 2017 Nov 16;7:276. doi: 10.3389/fonc.2017.00276. eCollection 2017. No abstract available.

4.

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.

Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC.

Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18.

PMID:
29361470
5.

The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications.

Duska LR, Kohn EC.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii8-viii12. doi: 10.1093/annonc/mdx445. Review.

PMID:
29232468
6.

Clinical trials in gynecologic oncology: Past, present, and future.

Annunziata CM, Kohn EC.

Gynecol Oncol. 2018 Feb;148(2):393-402. doi: 10.1016/j.ygyno.2017.11.026. Epub 2017 Dec 6. Review.

PMID:
29212614
7.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.

MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC.

Oncotarget. 2017 Aug 3;8(48):84579-84594. doi: 10.18632/oncotarget.19961. eCollection 2017 Oct 13. Review.

8.

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.

Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC.

Oncotarget. 2017 Mar 25;8(45):79175-79187. doi: 10.18632/oncotarget.16577. eCollection 2017 Oct 3.

9.

The HRD Decision-Which PARP Inhibitor to Use for Whom and When.

Kohn EC, Lee JM, Ivy SP.

Clin Cancer Res. 2017 Dec 1;23(23):7155-7157. doi: 10.1158/1078-0432.CCR-17-2186. Epub 2017 Oct 3.

PMID:
28974545
10.

The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality.

Ivy SP, de Bono J, Kohn EC.

Trends Cancer. 2016 Nov;2(11):646-656. doi: 10.1016/j.trecan.2016.10.014. Epub 2016 Nov 23. Review.

11.

Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers.

Peer CJ, Lee JM, Roth J, Rodgers L, Nguyen J, Annunziata CM, Minasian L, Kohn EC, Figg WD.

Cancer Chemother Pharmacol. 2017 Jul;80(1):165-175. doi: 10.1007/s00280-017-3346-1. Epub 2017 Jun 2.

PMID:
28577239
12.

Whence High-Grade Serous Ovarian Cancer.

Kohn EC, Ivy SP.

Am Soc Clin Oncol Educ Book. 2017;37:443-448. doi: 10.14694/EDBK_174718. Review.

13.

Drug development and registration: Challenges and opportunities in ovarian cancer.

Ivy SP, Kohn EC.

Cancer. 2017 Jul 15;123(14):2597-2599. doi: 10.1002/cncr.30645. Epub 2017 May 12. No abstract available.

14.

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.

Lee JM, Cimino-Mathews A, Peer CJ, Zimmer A, Lipkowitz S, Annunziata CM, Cao L, Harrell MI, Swisher EM, Houston N, Botesteanu DA, Taube JM, Thompson E, Ogurtsova A, Xu H, Nguyen J, Ho TW, Figg WD, Kohn EC.

J Clin Oncol. 2017 Jul 1;35(19):2193-2202. doi: 10.1200/JCO.2016.72.1340. Epub 2017 May 4.

15.

PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.

del Rivero J, Kohn EC.

Oncology (Williston Park). 2017 Apr 15;31(4):265-73. Review.

16.

Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP.

Yokoyama T, Kohn EC, Brill E, Lee JM.

Int J Oncol. 2017 Mar 15. doi: 10.3892/ijo.2017.3914. [Epub ahead of print]

17.

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.

Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM.

Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21.

18.

Words matter: Restoring respect and dignity when referring to individuals with cancer.

Ellis LM, Blanke CD, Kohn EC.

Cancer. 2017 Jul 1;123(13):2390-2391. doi: 10.1002/cncr.30625. Epub 2017 Feb 9. No abstract available.

19.

The generalizability of NCI-sponsored clinical trials accrual among women with gynecologic malignancies.

Mishkin G, Minasian LM, Kohn EC, Noone AM, Temkin SM.

Gynecol Oncol. 2016 Dec;143(3):611-616. doi: 10.1016/j.ygyno.2016.09.026. Epub 2016 Sep 30.

PMID:
27697287
20.

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.

Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou VL, Murphy RF, Widemann BC, Figg WD, Kohn EC.

Clin Cancer Res. 2017 Mar 15;23(6):1397-1406. doi: 10.1158/1078-0432.CCR-16-1546. Epub 2016 Sep 23.

21.

Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.

Kristeleit RS, Miller RE, Kohn EC.

Am Soc Clin Oncol Educ Book. 2016;35:e259-68. doi: 10.14694/EDBK_159086. Review.

22.

Confronting the Care Delivery Challenges Arising from Precision Medicine.

Kohn EC, Ivy SP.

Front Oncol. 2016 Apr 27;6:106. doi: 10.3389/fonc.2016.00106. eCollection 2016. Review.

23.

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.

Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC.

Expert Opin Investig Drugs. 2016;25(5):597-611. doi: 10.1517/13543784.2016.1156857. Epub 2016 Mar 16. Review.

PMID:
26899229
24.

Challenges and Opportunities for Immunotherapies in Gynecologic Cancers.

Lee JM, Ivy SP, Kohn EC.

Oncology (Williston Park). 2016 Jan;30(1):67-9. No abstract available.

25.

Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.

Noonan AM, Bunch KP, Chen JQ, Herrmann MA, Lee JM, Kohn EC, O'Sullivan CC, Jordan E, Houston N, Takebe N, Kinders RJ, Cao L, Peer CJ, Figg WD, Annunziata CM.

Cancer. 2016 Feb 15;122(4):588-597. doi: 10.1002/cncr.29783. Epub 2015 Nov 13.

26.

To Treat or Not to Treat: The Use of Hormone Replacement Therapy in Patients With Ovarian Cancer.

Lipkowitz S, Kohn EC.

J Clin Oncol. 2015 Dec 10;33(35):4127-8. doi: 10.1200/JCO.2015.63.6670. Epub 2015 Oct 5. No abstract available.

PMID:
26438113
27.

Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer.

Lee JM, Gordon N, Trepel JB, Lee MJ, Yu M, Kohn EC.

J Transl Med. 2015 Jul 22;13:239. doi: 10.1186/s12967-015-0604-z.

28.

Does one size fit all? The updated ovarian cancer staging: Still a work in progress.

Duska LR, Kohn EC.

Cancer. 2015 Oct 1;121(19):3384-6. doi: 10.1002/cncr.29521. Epub 2015 Jun 25. No abstract available.

29.

Ovarian cancer treatment: The end of empiricism?

Lheureux S, Karakasis K, Kohn EC, Oza AM.

Cancer. 2015 Sep 15;121(18):3203-11. doi: 10.1002/cncr.29481. Epub 2015 Jun 10. Review.

30.

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer.

Lee JM, Trepel JB, Choyke P, Cao L, Sissung T, Houston N, Yu M, Figg WD, Turkbey IB, Steinberg SM, Lee MJ, Ivy SP, Liu JF, Matulonis UA, Kohn EC.

Front Oncol. 2015 Jun 1;5:123. doi: 10.3389/fonc.2015.00123. eCollection 2015.

31.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA.

Lancet Oncol. 2014 Oct;15(11):1207-14. doi: 10.1016/S1470-2045(14)70391-2. Epub 2014 Sep 10.

32.

The MAPK pathway across different malignancies: a new perspective.

Burotto M, Chiou VL, Lee JM, Kohn EC.

Cancer. 2014 Nov 15;120(22):3446-56. doi: 10.1002/cncr.28864. Epub 2014 Jun 19. Review.

33.

Molecular profiling and commercial predication assays in ovarian cancer: still not ready for prime time?

Kohn EC.

Am Soc Clin Oncol Educ Book. 2014:139-47. doi: 10.14694/EdBook_AM.2014.34.139. Review.

34.

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.

J Natl Cancer Inst. 2014 May 19;106(6):dju089. doi: 10.1093/jnci/dju089. Print 2014 Jun.

35.

Ovarian cancer.

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA.

Lancet. 2014 Oct 11;384(9951):1376-88. doi: 10.1016/S0140-6736(13)62146-7. Epub 2014 Apr 21. Review.

PMID:
24767708
36.

State of the science in cervical cancer: where we are today and where we need to go.

Dizon DS, Mackay HJ, Thomas GM, Werner TL, Kohn EC, Hess D, Rose PG, Covens AL.

Cancer. 2014 Aug 1;120(15):2282-8. doi: 10.1002/cncr.28722. Epub 2014 Apr 15. Review.

37.

A phase II clinical trial of polyethylene glycol-conjugated L-asparaginase in patients with advanced ovarian cancer: Early closure for safety.

Hays JL, Kim G, Walker A, Annunziata CM, Lee JM, Squires J, Houston N, Steinberg SM, Kohn EC.

Mol Clin Oncol. 2013 May;1(3):565-569. Epub 2013 Mar 20.

38.

Better therapeutic trials in ovarian cancer.

Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD.

J Natl Cancer Inst. 2014 Apr;106(4):dju029. doi: 10.1093/jnci/dju029. Epub 2014 Mar 13. Review.

39.

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.

O'Sullivan CC, Moon DH, Kohn EC, Lee JM.

Front Oncol. 2014 Feb 28;4:42. doi: 10.3389/fonc.2014.00042. eCollection 2014. Review.

40.

Clinical implications of using molecular diagnostics for ovarian cancers.

Kohn EC, Romano S, Lee JM.

Ann Oncol. 2013 Dec;24 Suppl 10:x22-26. doi: 10.1093/annonc/mdt464. Review.

41.

PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.

Lee JM, Ledermann JA, Kohn EC.

Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12. Review.

42.

Novel facts about FAK: new connections to drug resistance?

Annunziata CM, Kohn EC.

J Natl Cancer Inst. 2013 Oct 2;105(19):1430-1. doi: 10.1093/jnci/djt255. Epub 2013 Sep 23. No abstract available.

PMID:
24062526
43.

Personalized oncology in interventional radiology.

Abi-Jaoudeh N, Duffy AG, Greten TF, Kohn EC, Clark TW, Wood BJ.

J Vasc Interv Radiol. 2013 Aug;24(8):1083-92; quiz 1093. doi: 10.1016/j.jvir.2013.04.019. Review.

44.

Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.

Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.

Br J Cancer. 2013 Aug 20;109(4):1072-8. doi: 10.1038/bjc.2013.389. Epub 2013 Jul 18.

45.

Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.

Azad N, Yu M, Davidson B, Choyke P, Chen CC, Wood BJ, Venkatesan A, Henning R, Calvo K, Minasian L, Edelman DC, Meltzer P, Steinberg SM, Annunziata CM, Kohn EC.

Mol Cell Proteomics. 2013 Jun;12(6):1621-31. doi: 10.1074/mcp.M112.026427. Epub 2013 Feb 28.

46.

Feasibility and safety of sequential research-related tumor core biopsies in clinical trials.

Lee JM, Hays JL, Noonan AM, Squires J, Minasian L, Annunziata C, Wood BJ, Yu M, Calvo KR, Houston N, Azad N, Kohn EC.

Cancer. 2013 Apr 1;119(7):1357-64. doi: 10.1002/cncr.27916. Epub 2012 Dec 20.

47.

Ovarian cancer : making its own rules-again.

Kohn EC, Hurteau J.

Cancer. 2013 Feb 1;119(3):474-6. doi: 10.1002/cncr.27833. Epub 2012 Dec 11. Review. No abstract available.

48.

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.

Annunziata CM, Kohn EC, LoRusso P, Houston ND, Coleman RL, Buzoianu M, Robbie G, Lechleider R.

Invest New Drugs. 2013 Feb;31(1):77-84. doi: 10.1007/s10637-012-9801-2. Epub 2012 Feb 28.

49.

L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer.

Yu M, Henning R, Walker A, Kim G, Perroy A, Alessandro R, Virador V, Kohn EC.

J Cell Mol Med. 2012 Oct;16(10):2369-78. doi: 10.1111/j.1582-4934.2012.01547.x.

50.

Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion.

Mineo M, Garfield SH, Taverna S, Flugy A, De Leo G, Alessandro R, Kohn EC.

Angiogenesis. 2012 Mar;15(1):33-45. doi: 10.1007/s10456-011-9241-1. Epub 2011 Dec 22.

Supplemental Content

Support Center